Terumo faces $610 million charge after losing major US plasma customer

Terumo Corporation, one of Asia's leading medical device manufacturers, disclosed a $610 million charge related to the loss of a significant customer contract for its plasma collection device in the United States. The Tokyo-based company said the charge reflects the impact of losing this major revenue stream from its plasma business segment.

The Japanese manufacturer specializes in blood management and plasma collection technologies serving hospitals and blood centers across multiple markets. The loss of the US customer represents a substantial setback for the company's plasma device operations, which had been a key component of its healthcare equipment portfolio.

Terumo did not immediately disclose the identity of the lost customer or provide detailed circumstances surrounding the contract termination. The company indicated it would implement measures to mitigate the financial impact and reassess its strategy in the plasma collection equipment sector.

The charge underscores competitive pressures in the medical device market, particularly in specialized segments like plasma collection technology. Industry analysts note that changes in hospital procurement decisions and customer consolidation can significantly affect device manufacturers' financial performance.